Also in breast cancer, in particular the triple-negative type, it has been seen that the expression of potassium channels determines increased in vitro invasion, tumor growth in vivo, and metastases, so it is interesting to reposition already approved potassium channel-blocking drugs for the therapy of this type of particularly aggressive cancer [219,220]. Here, KCNA3 is linked to neoplasm.